ERBB2 and breast carcinoma: Given the successful usage of PI3Kα inhibitor in luminal (HR+) breast cancer, we next tested whether a dual blockade strategy could effectively inhibit mutated‐PI3Kα and enriched‐HER2 simultaneously.